Tag Archives: Cellectis

June, 2018

November, 2017

September, 2017

February, 2017

  • 8 February

    Cellectis Gains FDA Approval to Test New Gene Edited CAR T-Cell Therapy

    NEW YORK–(BUSINESS WIRE)–Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART), has received an Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) to conduct Phase 1 clinical trials with UCART123, the Company’s …

November, 2015

  • 19 November

    Servier and Pfizer Get Rights to Cellectis CAR-T Therapy

    November 19, 2015 – New York (USA) and Suresnes (France) – Cellectis (Alternext: ALCLS; Nasdaq: CLLS) and Servier today announced that they signed an amendment to their existing collaboration agreement from February 2014 especially for UCART19, a TALEN® gene-edited allogeneic Chimeric Antigen Receptor T-cell (CAR-T) immunotherapy. Under this amendment, Servier …